Chemomab Therapeutics (CMMB) Change in Accured Expenses (2019 - 2023)

Chemomab Therapeutics' Change in Accured Expenses history runs 5 years deep, the most recent figure standing at $416000.0 for Q4 2023.

• Quarterly Change in Accured Expenses rose 137.31% year-over-year to $416000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $45000.0 (down 95.04% YoY) and the FY2025 annual result came in at -$278000.0, up 85.27% from the prior year.
• Change in Accured Expenses was $416000.0 for Q4 2023 at Chemomab Therapeutics, down from $504000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $1.1 million in Q2 2022 and bottomed at -$1.1 million in Q4 2022.
• A 5-year average of $83100.0 and a median of $49000.0 in 2021 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2020 — Change in Accured Expenses jumped 518.39% — and 2023, when it tumbled 1746.15%.
• Chemomab Therapeutics' Change in Accured Expenses stood at $922000.0 in 2019, then slumped by 89.48% to $97000.0 in 2020, then surged by 108.25% to $202000.0 in 2021, then tumbled by 651.98% to -$1.1 million in 2022, then soared by 137.31% to $416000.0 in 2023.
• Business Quant data shows CMMB's Change in Accured Expenses at $416000.0 in Q4 2023, $504000.0 in Q3 2023, and -$661000.0 in Q2 2023.